ROCKVILLE, Maryland, Aug. 20, 2019 /PRNewswire/ -- As per this Fact.MR report, there has been an evident surge in the prevalence of gonorrhea which is resistant to components of dual antibiotic therapy – azithromycin and ceftriaxone, known to be the only suggested treatment for gonorrhea. With a swing of hopeful new antibiotics together with education, surveillance and preventative measures to impasse prevalence of super-resistant gonorrhea, the prospects seem optimistic for the gonorrhea therapeutics market. In order to acquire better insight into the gonorrhea therapeutics market, Fact.MR has published this study titled "Gonorrhea Therapeutics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029", which provides detailed information associated to the growth forecast of the target market, along with a structured breakdown of the aspects shaping the market dynamics.
According to this intelligent report, the gonorrhea therapeutics market is likely to reach ~US$ 970 Mn in 2019, with an estimated 4% Y-o-Y growth over 2018. It has been observed that gonorrhea therapeutics industry would remain prejudiced by increased attention towards new developments in novel therapeutic antimicrobials or compounds for refining the success potential of upcoming treatment.
Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=3761
Azithromycin Sales Likely to Prosper with Rising Regional Preference
This study highlights that sales of azithromycin would continue to deliver greater gains across the gonorrhea treatment market. This growth is narrowly trailed by the third-generation cephalosporin which is also gaining high-end traction. As per this assessment, azithromycin sales concerned with the treatment of gonorrhea are likely to acquire ~50% market shares. On the other hand, sales of third-generation cephalosporin are anticipated to surge at a pace similar to that of azithromycin in the near future. There are several countries which have worked to increase the doses of the suggested gonorrhea drugs with an aim to overcome the bacteria's resistance.
Dual Therapy Stays as the Favored Treatment Choice
Looking at the current scenario, the market for gonorrhea therapeutics is expected to propel in parallel with the theoretically effective drugs which are presently in pipeline. With a significant rise in the count of clinical trials and growing investments in healthcare industry, the scope for lucrative avenues in the gonorrhea therapeutics market are quite robust. This study reveals that dual therapy will continue its status as the preferred treatment choice for gonorrhea, accounting ~90% market shares. This abides the current recommended routine for gonorrhea treatment that covers a combination of two antibiotics, ceftriaxone, an intra-muscular drug and azithromycin, which is provided orally.
Get Report Overview- https://www.factmr.com/report/3761/gonorrhea-therapeutics-market
North America and Europe Set to Deliver Encouraging Opportunities
Based on this Fact.MR study, promising nature of developed markets such as North America and Europe, is likely to endure positive results for gonorrhea therapeutics. The concerned market in these regions is primarily supported by rising prevalence of STDs and advancing healthcare infrastructure. According to recent assessments, close to ~1 Mn cases of gonorrhea have been reported annually in the U.S. The key growth influencers are spotted to be favorable reimbursement policies as well as government funding towards several health organizations for the expansion of drug-resistant gonorrhea treatment.
As the report concludes, readers can access knowledge associated to the prime companies contributing towards the development of the global gonorrhea therapeutics market. Some of the leading players mentioned in the report are Bayer AG, GlaxoSmithKline Plc., Pfizer Inc., Allergan plc, Novartis AG, Mylan N.V etc.
Request Methodology of this Report- https://www.factmr.com/connectus/sample?flag=RM&rep_id=3761
More Healthcare Industry Market Reports from Fact.MR
Oncology Small Molecule Drugs Market- The market for oncology small molecule drugs is envisaged to register ~6% CAGR through 2029, primarily driven by rapid technological advancement in healthcare sector that continues to pave way for new and improved product development. North America, spearheaded by the U.S., is anticipated to remain the leading as well as high growth market for oncology small molecule drugs during the foreseeable period.
MRI-guided Radiation Therapy Systems Market- The Magnetic Resonance Imaging (MRI)-guided radiation therapy systems market was valued at nearly US$ 221 Mn in 2018, and is expected to register 31% y-o-y growth in 2019. The MRI-guided radiation therapy systems industry has been underpinned by the emergence of advanced technologies in healthcare and medical devices industries. Increasing adoption of radiotherapy in cancer treatment is fuelling demand for MRI-guided radiation therapy systems. The MRI-guided radiation therapy systems market is projected to record a CAGR of approximately 20% through 2028.
Pregnancy Point of Care Testing Market- The global pregnancy point of care testing market is likely to envisage incremental growth at a healthy 4.5% CAGR during the forecast period 2018-2028. Technological advancements and awareness about the accuracy and efficiency of pregnancy point of care testing products will contribute to increasing growth of the market during the assessment period. Backed by strong presence of leading market players in the U.S., North America will continue to remain the leading market for pregnancy point of care testing products throughout the forecast period.
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.